Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
500 pregnant patients with HBeAg-positive and HBV-DNA≥ 106copies /ml who will do their
pregnant check in the First Affiliated Hospital of Xi'an Jiaotong University will be enrolled
into the study. There will be five groups to be observed. Four groups are taking tenofovir to
prevent intrauterine infection during pregnancy. One group is not taking any anti-HBV virus
treatments.The clinical value and effectiveness of tenofovir on blocking HBV intrauterine
infection will be evaluated; The HBV-DNA infection status of placenta tissue will be checked
by quantitative Polymerase Chain Reaction (PCR) to assess the changes of HBV-DNA of placenta
after treating with tenofovir and explore the mechanism of tenofovir blocking HBV
intrauterine infection. The safety of Tenofovir will be assessed as well.
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University